Scarica l'app Stockscreener
203.06
0.38%
-0.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$203.83
Aprire:
$205.53
Volume 24 ore:
898.84K
Relative Volume:
1.01
Capitalizzazione di mercato:
$22.48B
Reddito:
$11.28B
Utile/perdita netta:
$1.07B
Rapporto P/E:
22.40
EPS:
9.0657
Flusso di cassa netto:
$1.33B
1 W Prestazione:
+1.38%
1M Prestazione:
+6.77%
6M Prestazione:
+11.23%
1 anno Prestazione:
+13.42%
Intervallo 1D:
$202.38
$205.96
Intervallo di 1 settimana:
$196.70
$207.50
Portata 52W:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
203.06 | 22.48B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
469.34 | 174.42B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
180.10 | 127.47B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.88 | 44.24B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
129.84 | 36.67B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
355.53 | 34.91B | 3.77B | 449.25M | 240.68M | 7.8556 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest Diagnostics Inc (NYSE:DGX): A Top Dividend Stock with Sustainable Income and Growth Potential - ChartMill
Quest Diagnostics Incorporated (DGX) stock price, news, quote and history - Yahoo Finance Australia
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, LifeStance Health and Aveanna Healthcare - Yahoo Finance
TD Asset Management Inc Sells 65,893 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc (DGX) Shares Surge 3.7% -- What GF Score o - GuruFocus
Quest Diagnostics Inc (DGX) Shares Surge 3.7% -- What GF Score of 83 Tells Investors - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics stock: Analyst estimates & ratings - MSN
4 Outpatient Home Health Stocks Benefiting From Industry Trends - TradingView
Fox Run Management L.L.C. Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Purchased by Cibc World Market Inc. - MarketBeat
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity - Stock Titan
Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 7,700 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Bank of New York Mellon Corp Has $116.39 Million Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
[144] QUEST DIAGNOSTICS INC SEC Filing - Stock Titan
How The Quest Diagnostics (DGX) Investment Story Is Evolving Without New Analyst Price Target Changes - Yahoo Finance
BNP Paribas Financial Markets Purchases 6,487 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Insider Sold Shares Worth $1,941,400, According to a Recent SEC Filing - marketscreener.com
Insider Sell: J. Davis Sells 10,000 Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Quest Diagnostics CEO sells $1.94 million in company stock - Investing.com UK
Quest Diagnostics CEO sells $1.94 million in company stock By Investing.com - Investing.com Australia
Quest Diagnostics (DGX) CEO sells 10,000 shares in Rule 10b5-1 trade - Stock Titan
Affiliate sale notice — DGX (DGX) to sell 10,000 shares - Stock Titan
DGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Wall Street Zen Downgrades Quest Diagnostics (NYSE:DGX) to Hold - MarketBeat
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Legal & General Group Plc Has $128.93 Million Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year? - Yahoo Finance
Quest Diagnostics Stock: Analyst Estimates & Ratings - Yahoo Finance
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting - Investing.com India
Quest Diagnostics 8-K SEC Filing May 2026: Shareholder Vote Results and Company Information - Minichart
Quest Diagnostics (DGX) Announces Results of 2026 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com South Africa
Quest Diagnostics (DGX) director granted 1,142 restricted stock units in Form 4 filing - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 RSUs - Stock Titan
Quest Diagnostics (DGX) director receives 1,142-share restricted stock unit grant - Stock Titan
Quest Diagnostics (DGX) director gets 1,142-share restricted stock unit award - Stock Titan
Director Tracey Doi of Quest Diagnostics (DGX) receives 1,142-share equity award - Stock Titan
Director at Quest Diagnostics (DGX) awarded 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 stock units - Stock Titan
Quest Diagnostics (DGX) director receives 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (DGX) receives 1,142 share units - Stock Titan
Quest Diagnostics (NYSE: DGX) details 2026 shareholder votes on board, pay and auditor - Stock Titan
Why is Quest Diagnostics (DGX) down 5% since last earnings report? - MSN
Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report? - Yahoo Finance
Quest Diagnostics Keeps Quarterly Dividend at $0.86 a Share, Payable July 22 to Holders of Record July 8 - marketscreener.com
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):